QQQ   444.96 (-0.15%)
AAPL   174.39 (-2.93%)
MSFT   415.73 (+0.06%)
META   500.37 (-0.38%)
GOOGL   132.58 (-3.33%)
AMZN   178.10 (-0.07%)
TSLA   187.41 (-7.52%)
NVDA   869.44 (+5.67%)
NIO   5.29 (-8.48%)
AMD   207.71 (+2.50%)
BABA   71.90 (-3.65%)
T   16.79 (-1.12%)
F   12.86 (+3.29%)
MU   96.75 (+1.68%)
CGC   3.01 (-6.23%)
GE   160.89 (+1.41%)
DIS   113.58 (+1.46%)
AMC   4.31 (-1.15%)
PFE   25.72 (-3.27%)
PYPL   59.74 (-1.32%)
XOM   104.43 (-1.33%)
QQQ   444.96 (-0.15%)
AAPL   174.39 (-2.93%)
MSFT   415.73 (+0.06%)
META   500.37 (-0.38%)
GOOGL   132.58 (-3.33%)
AMZN   178.10 (-0.07%)
TSLA   187.41 (-7.52%)
NVDA   869.44 (+5.67%)
NIO   5.29 (-8.48%)
AMD   207.71 (+2.50%)
BABA   71.90 (-3.65%)
T   16.79 (-1.12%)
F   12.86 (+3.29%)
MU   96.75 (+1.68%)
CGC   3.01 (-6.23%)
GE   160.89 (+1.41%)
DIS   113.58 (+1.46%)
AMC   4.31 (-1.15%)
PFE   25.72 (-3.27%)
PYPL   59.74 (-1.32%)
XOM   104.43 (-1.33%)
QQQ   444.96 (-0.15%)
AAPL   174.39 (-2.93%)
MSFT   415.73 (+0.06%)
META   500.37 (-0.38%)
GOOGL   132.58 (-3.33%)
AMZN   178.10 (-0.07%)
TSLA   187.41 (-7.52%)
NVDA   869.44 (+5.67%)
NIO   5.29 (-8.48%)
AMD   207.71 (+2.50%)
BABA   71.90 (-3.65%)
T   16.79 (-1.12%)
F   12.86 (+3.29%)
MU   96.75 (+1.68%)
CGC   3.01 (-6.23%)
GE   160.89 (+1.41%)
DIS   113.58 (+1.46%)
AMC   4.31 (-1.15%)
PFE   25.72 (-3.27%)
PYPL   59.74 (-1.32%)
XOM   104.43 (-1.33%)
QQQ   444.96 (-0.15%)
AAPL   174.39 (-2.93%)
MSFT   415.73 (+0.06%)
META   500.37 (-0.38%)
GOOGL   132.58 (-3.33%)
AMZN   178.10 (-0.07%)
TSLA   187.41 (-7.52%)
NVDA   869.44 (+5.67%)
NIO   5.29 (-8.48%)
AMD   207.71 (+2.50%)
BABA   71.90 (-3.65%)
T   16.79 (-1.12%)
F   12.86 (+3.29%)
MU   96.75 (+1.68%)
CGC   3.01 (-6.23%)
GE   160.89 (+1.41%)
DIS   113.58 (+1.46%)
AMC   4.31 (-1.15%)
PFE   25.72 (-3.27%)
PYPL   59.74 (-1.32%)
XOM   104.43 (-1.33%)
OTCMKTS:DTCFF

Defence Therapeutics (DTCFF) Stock Price, News & Analysis

$1.35
0.00 (0.00%)
(As of 03/1/2024 ET)
Today's Range
$1.35
$1.35
50-Day Range
$1.25
$1.74
52-Week Range
$1.25
$4.47
Volume
N/A
Average Volume
440 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

DTCFF stock logo

About Defence Therapeutics Stock (OTCMKTS:DTCFF)

Defence Therapeutics Inc. engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

DTCFF Stock Price History

DTCFF Stock News Headlines

Defence Therapeutics (OTCMKTS:DTCFF) Shares Down 1.5%
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Defence Therapeutics Completes 1st Tranche of Financing
Defence Financing
Defence Therapeutics Inc DTCFF
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Defence Therapeutics Inc (DTC)
See More Headlines
Receive DTCFF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Defence Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:DTCFF
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Sebastien Plouffe (Age 52)
    CEO, President & Director
    Comp: $83.11k
  • Mr. Patrick Joseph Meagher C.A. (Age 38)
    CPA, CA, CPA, CFO & Director
    Comp: $58.73k
  • Dr. Moutih Rafei Ph.D. (Age 42)
    Chief Scientific Officer & Director
    Comp: $9.23k
  • Dr. Simon Beaudoin (Age 39)
    Chief Technical Science Officer
  • Ms. Carrie Cesarone (Age 59)
    Corporate Secretary














DTCFF Stock Analysis - Frequently Asked Questions

How have DTCFF shares performed in 2024?

Defence Therapeutics' stock was trading at $1.65 on January 1st, 2024. Since then, DTCFF stock has decreased by 18.2% and is now trading at $1.3501.
View the best growth stocks for 2024 here
.

How do I buy shares of Defence Therapeutics?

Shares of DTCFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:DTCFF) was last updated on 3/4/2024 by MarketBeat.com Staff